| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3325927 | NPG Neurologie - Psychiatrie - Gériatrie | 2015 | 6 Pages |
Abstract
Since 2006, the live attenuated vaccine against shingles has had market authorisation in the European Union. Since June 15th 2015, it is available in France for the price of 127.24 ⬠and will be reimbursed by the National Health Insurance System. This article answers your questions about its interest, efficacy, tolerance and benefits to society in the prevention of shingles and one of its the most frequent and most disabling complications: post-herpetic neuralgia.
Related Topics
Health Sciences
Medicine and Dentistry
Geriatrics and Gerontology
Authors
P.-O. Lang, C. Trivalle,